# KIMCO

> KIMCO is a VC fund in Seocho backing Biotechnology, Pharmaceutical and Genetics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seocho, South Korea
- Total investments: 3
- Last investment: Jul 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://www.kimc.or.kr/

KIMCO (The Korea Innovative Medicines Consortium) is an incorporated foundation established with the aspiration of innovative growth through open innovationin the bio-pharma industry.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Pharmaceutical | 2 | 67% |
| Genetics | 1 | 33% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 2 | 67% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ArcGen Bioscience | ArcGen Bioscience is a biopharmaceutical development company focused on researching, developing, and advancing innovative therapeutic solutions to address unmet medical needs through cutting-edge biotechnology and drug development. | $6.7M | Series A | Jul 13, 2026 |  |
| Inventera Pharmaceuticals | Inventera Pharmaceutical is a biotechnology company that specializes in the development of imaging diagnostic contrast agents. | $13.4M | Series C | Oct 30, 2024 |  |
| BreezeBio | GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $24M | Series A | Jan 23, 2024 |  |

3 of 3 investments shown.

## Co-investors
- [Huons](https://shizune.co/investors/profile/huons) — VC Fund, 2 deals together
- [Woori Venture Partners](https://shizune.co/investors/profile/woori-venture-partners) — VC Fund, 2 deals together
- [Yuanta Investment](https://shizune.co/investors/profile/yuanta-investment) — VC Fund, 2 deals together
- [ACVC](https://shizune.co/investors/profile/acvc) — VC Fund, 1 deal together
- Chungbuk Creative Economy Innovation Center — VC Fund, 1 deal together
- Dong-A ST — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does KIMCO invest in?

KIMCO invests primarily in Biotechnology, Pharmaceutical and Genetics startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did KIMCO last invest?

The most recent investment recorded for KIMCO closed in Jul 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co